Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03733119
What this trial is testing

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
University of Wisconsin, Madison 4
Not applicableLooking for participantsNCT07332975
What this trial is testing

CtDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

Who this might be right for
Triple Negative Breast Cancer
University of Pittsburgh 77
Testing effectiveness (Phase 2)Looking for participantsNCT06802757
What this trial is testing

Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Shandong Cancer Hospital and Institute 72
Not applicableNot Yet RecruitingNCT07357948
What this trial is testing

Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy

Who this might be right for
Triple Negative Breast CancerNon-Metastatic
Institut Curie 150
Testing effectiveness (Phase 2)Study completedNCT02580448
What this trial is testing

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

Who this might be right for
Cancer of the BreastBreast CancerAdvanced Breast Cancer+4 more
Innocrin Pharmaceutical 175
Large-scale testing (Phase 3)Looking for participantsNCT05812807
What this trial is testing

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Early Stage Triple-Negative Breast CarcinomaAnatomic Stage IIIA Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology 1,295
Early research (Phase 1)Ended earlyNCT02476955
What this trial is testing

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Who this might be right for
Solid TumorsOvarian CancerEndometrial Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Testing effectiveness (Phase 2)Study completedNCT01306032
What this trial is testing

Phase II ABT-888 With Cyclophosphamide

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerSerous Carcinoma Cancer+2 more
National Cancer Institute (NCI) 124
Large-scale testing (Phase 3)Study completedNCT00022516
What this trial is testing

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 1,086
Not applicableNot Yet RecruitingNCT07662252
What this trial is testing

Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer (TNBC)HER2 + Breast Cancer
Federico II University 186
Testing effectiveness (Phase 2)Ended earlyNCT04504916
What this trial is testing

Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Who this might be right for
Triple-negative Breast CancerNon-squamous Non-small-cell Lung CancerNSCLC+12 more
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 102
Early research (Phase 1)WithdrawnNCT06590558
What this trial is testing

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+9 more
National Cancer Institute (NCI)
Not applicableLooking for participantsNCT07258563
What this trial is testing

The TASTY-steering Study

Who this might be right for
Metastatic Triple Negative Breast CancerMetastatic Testicular CancerStage II-IV Diffuse Large B Cell Lymphoma
University Medical Center Groningen 201
Testing effectiveness (Phase 2)Active Not RecruitingNCT05498896
What this trial is testing

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

Who this might be right for
Triple Negative Breast Cancer
Queen Mary University of London 146
Testing effectiveness (Phase 2)UnknownNCT04303988
What this trial is testing

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Who this might be right for
Breast Cancer
Fudan University 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT06612203
What this trial is testing

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
MedSIR 76
Testing effectiveness (Phase 2)UnknownNCT05386524
What this trial is testing

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Who this might be right for
Breast Cancer
Fudan University 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT03594396
What this trial is testing

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Who this might be right for
Breast Neoplasms
Seoul National University Hospital 54
Early research (Phase 1)Looking for participantsNCT06465069
What this trial is testing

LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Who this might be right for
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11 more
Eli Lilly and Company 420
Not applicableLooking for participantsNCT06774027
What this trial is testing

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Who this might be right for
HER2-negative Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast Cancer+3 more
University of California, San Francisco 100
Next Page